Eloxx Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ELOX Nasdaq 8731 https://www.eloxxpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference - Mar 6th, 2023 9:10 pm
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed - Feb 27th, 2023 9:05 pm
Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidate - Feb 24th, 2023 1:01 pm
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome - Jan 25th, 2023 1:00 pm
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective - Dec 1st, 2022 1:45 pm
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update - Nov 10th, 2022 10:15 pm
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome - Nov 1st, 2022 8:30 pm
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal - Sep 16th, 2022 3:42 pm
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients - Sep 14th, 2022 8:05 pm
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update - Aug 15th, 2022 12:00 pm
Eloxx Pharmaceuticals Announces Changes to Board of Directors - Jul 5th, 2022 12:00 pm
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update - May 10th, 2022 12:00 pm
Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update - Mar 31st, 2022 11:00 am
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome - Mar 30th, 2022 8:15 pm
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation - Mar 29th, 2022 11:00 am